Cue Biopharma (NASDAQ:CUE – Get Free Report) and Coya Therapeutics (NASDAQ:COYA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Institutional and Insider Ownership
35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Cue Biopharma and Coya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cue Biopharma | -435.83% | -620.06% | -291.15% |
| Coya Therapeutics | -270.22% | -52.05% | -46.34% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Biopharma | $27.47 million | 7.25 | -$26.60 million | ($27.02) | -1.02 |
| Coya Therapeutics | $7.95 million | 14.70 | -$21.23 million | ($1.07) | -4.65 |
Coya Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Coya Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Cue Biopharma has a beta of 2.45, suggesting that its stock price is 145% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Cue Biopharma and Coya Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Biopharma | 1 | 1 | 0 | 1 | 2.33 |
| Coya Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
Cue Biopharma currently has a consensus price target of $83.00, indicating a potential upside of 202.37%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 207.90%. Given Coya Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than Cue Biopharma.
Summary
Coya Therapeutics beats Cue Biopharma on 10 of the 15 factors compared between the two stocks.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
About Coya Therapeutics
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
